A detailed history of Alpha Centric Advisors LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Alpha Centric Advisors LLC holds 12,500 shares of CYTK stock, worth $638,625. This represents 0.56% of its overall portfolio holdings.

Number of Shares
12,500
Holding current value
$638,625
% of portfolio
0.56%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

BUY
$51.22 - $60.16 $640,250 - $752,000
12,500 New
12,500 $660,000
Q2 2021

Mar 09, 2022

SELL
$19.79 - $26.99 $247,375 - $337,375
-12,500 Closed
0 $0
Q4 2020

Mar 11, 2022

BUY
$15.26 - $28.61 $190,750 - $357,625
12,500 New
12,500 $260,000

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.81B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Alpha Centric Advisors LLC Portfolio

Follow Alpha Centric Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Centric Advisors LLC with notifications on news.